This is a Request for Information and Sources Sought Notice from BARDA to refine requirements and conduct market research for host-directed therapeutics to prevent ARDS in hospitalized patients with viral respiratory infections. The agency is considering establishing long-term partnerships with multiple contractors to advance late-stage clinical development, specifically seeking a Phase 3 clinical development plan for a product with supportive Phase 2 data. Responses are requested by 3:00 pm EDT on April 15, 2026. The notice outlines mandatory eligibility criteria, including demonstrated efficacy against severe viral respiratory infection and FDA feedback on Phase 3 study design. It is for planning purposes only and does not constitute a formal solicitation.